GLTO
Galecto, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.58
−3.36%Price chart
Jun 2Jun 5Jun 10Jun 15Jun 18Jun 24Jun 29Jul 2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.6x
Market Cap
$28.64M
MomentumView details →
1D Return
−3.36%
YTD Return
+30.29%
RSI (14)
70.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.6x
Market Cap
$28.64M
RSI (14)
70.7
MomentumView details →
1D Return
−3.36%
YTD Return
+30.29%
SummaryUpdated Mar 1, 2026
Galecto, Inc. (NASDAQ:GLTO) is a clinical-stage biotechnology company founded in 2011 and based in Boston, Massachusetts. The company went public in October 2020 and focuses on developing therapeutic molecules targeting galectin proteins for the treatment of fibrosis, cancer, and inflammatory diseases. Galecto operates as a pre-revenue biotech company with multiple drug candidates in various phases of clinical trials, representing a specialized approach to treating diseases characterized by abnormal tissue scarring and immune dysfunction.
Similar companies
Latest newsMore news →
Damora Therapeutics initiated the global Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis, following health authority approval.31d agoDamora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026.50d ago